MOBILE, Alabama -- The Baldwin County doctor that treated former Alabama football players with adult stem cells also has treated at least two people diagnosed with amyotrophic lateral sclerosis, also known as Lou Gehrigs disease. One of the ALS patients, former NFL football player and college coach Frank Orgel, recently underwent a new stem cell reprogramming technique performed by Dr. Jason R. Williams at Precision StemCell in Gulf Shores. Before the injections, Orgels health had declined. He could not move his left arm or leg. He couldnt walk or stand on his own, he said. Within a few days of having the stem cell treatment, Orgels constant muscle twitching diminished, said Bob Hubbard, director of stem cell therapy at the practice. Within weeks, he was able to walk in a pool of water and stand unassisted. I think its helped me, said Orgel, who was a defensive coordinator at Auburn under former head coach Pat Dye. Im walking in the pool and I used to drag my feet. Now my left leg is picking up. ALS is a progressive neuro-degenerative disease that affects nerve cells in the brain and the spinal cord. The progressive degeneration of the motor neurons in … Continue reading →

Public release date: 29-Jun-2012 [ | E-mail | Share ] Contact: Elisabeth (Lisa) Lyons elyons@cell.com 617-386-2121 Cell Press Latest annual citation reports confirm Cell Press delivers highly valued, highly cited research and reviews to the scientific community it serves We are delighted to report that the new impact factors align with community perception and confirm that Cell Press continues to publish the highest impact research and reviews in the biomedical sciences, according to the latest Journal Citation Reports published by Thomas Reuters. Cell Press's flagship journal Cell received an impressive impact factor of 32.403. Showing strong and steady growth, Cell's impact factor has increased by 9% since 2005, maintaining its status as the premier research journal in its field. Cell is currently ranked the number one research journal in the 'Cell Biology' and 'Biochemistry & Molecular Biology' categories. Over 70% of journals within the Trends review journal series increased in impact factor this year, with significant growth across several life science disciplines. Top performers include Trends in Cognitive Science, which increased by 30% to 12.586, Trends in Immunology, which grew 9% to 10.403, and Trends in Ecology and Evolution, which rose 9% to 15.748. Published by Cell Press since 2007, … Continue reading →

28-06-2012 13:54 About 5 months ago, she came home from the beach with my husband limping on her right back leg. Now 8 weeks later after stem cell therapy... we were happy (well, maybe not so much...) to see her back to her old, wild, hyper self again. More here: Ipo 8 weeks after stem cell therapy at Surf Paws Animal Hospital - Video … Continue reading →

28-06-2012 14:46 More here: Stem Cell Therapy | Producers Direct | Kansas City, Missouri - Video … Continue reading →

SAN DIEGO CA--(Marketwire -06/29/12)- Medistem Inc. (MEDS) announced today notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent covering the use of fat stem cells, and cells associated with fat stem cells for treatment of diseases related to a dysfunctional immune system. Such diseases include multiple sclerosis, Type 1 diabetes, rheumatoid arthritis and lupus. The allowed patent, entitled "Stem Cell Mediated Treg Activation/Expansion for Therapeutic Immune Modulation" has the earliest priority date of December 2006. "We have previously published that giving multiple sclerosis patients cells extracted from their own fat tissue, which contains stem cells, appears to confer clinical benefit in a pilot study," said Thomas Ichim, CEO of Medistem. "The current patent that has been allowed, in the broadest interpretation of the claims, gives us exclusive rights to the use of specific types of fat stem cell therapy for autoimmune diseases such as multiple sclerosis." Subsequent to the filing of the patent application, Medistem together with collaborators at the Lawson Health Sciences Research Institute, Canada, reported data that fat tissue contains high numbers of T regulatory cells, a type of immune cell that is capable of controlling autoimmunity. This finding was independently confirmed … Continue reading →

COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today the expansion of its intellectual property protection around Prochymal (remestemcel-L). The United States Patent and Trademark Office recently granted Osiris two patents that cover multiple mechanisms of action related to cardiac tissue repair. Additionally, Osiris has enhanced its mesenchymal stem cell (MSC) patent estate with the issuance of patents across Europe and Australia covering stem cells expressing all therapeutically useful levels of cell surface receptors for TNF-alpha, a receptor essential to the cell's ability to counteract inflammation. These patents further support Osiris' considerable intellectual property position, which includes 48 issued U.S. patents around the production, composition, testing and use of the mesenchymal stem cell from both allogeneic and autologous sources. These recent additions to Osiris patent estate, combined with the existing broad coverage of our pioneering MSC platform technology, reinforce our industry leading IP portfolio and bolster our dominant position regarding the manufacture and use of mesenchymal stem cells for the treatment of a broad range of diseases "These recent additions to Osiris patent estate, combined with the existing broad coverage of our pioneering MSC platform technology, reinforce our industry leading IP portfolio and bolster our dominant position regarding the manufacture … Continue reading →